Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Deng, M.
Right arrow Articles by Daley, G. Q.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Deng, M.
Right arrow Articles by Daley, G. Q.
Related Collections
Right arrow Immunobiology
Right arrow Neoplasia
Right arrow Signal Transduction
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

Blood, 1 June 2001, Vol. 97, No. 11, pp. 3491-3497

IMMUNOBIOLOGY

Expression of interferon consensus sequence binding protein induces potent immunity against BCR/ABL-induced leukemia

Ming Deng and George Q. Daley

From the Whitehead Institute, Cambridge, Massachusetts, and Division of Hematology/Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.

Mice deficient in the interferon consensus sequence binding protein (ICSBP) develop a disease resembling chronic myeloid leukemia (CML), which in humans is caused by the BCR/ABL oncoprotein. Interferon-alpha (IFN-alpha ) induces ICSBP expression and is an effective therapy for CML. This study examined whether enforced expression of ICSBP might antagonize BCR/ABL-induced leukemia; results demonstrated that ICSBP-modified cells generated a protective CD8+ cytotoxic T-cell response against BCR/ABL-transformed BaF3 cells in a murine leukemia model. ICSBP expression represents a novel means of stimulating a host immune response to BCR/ABL+ leukemia cells and a potential strategy for immunotherapy of CML.

© 2001 by The American Society of Hematology.
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 BloodHome page
J. Koenigsmann, C. Rudolph, S. Sander, O. Kershaw, A. D. Gruber, L. Bullinger, B. Schlegelberger, and D. Carstanjen
Nf1 haploinsufficiency and Icsbp deficiency synergize in the development of leukemias
Blood, May 7, 2009; 113(19): 4690 - 4701.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
V. Nardi, O. Naveiras, M. Azam, and G. Q. Daley
ICSBP-mediated immune protection against BCR-ABL-induced leukemia requires the CCL6 and CCL9 chemokines
Blood, April 16, 2009; 113(16): 3813 - 3820.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
N. Dror, N. Rave-Harel, A. Burchert, A. Azriel, T. Tamura, P. Tailor, A. Neubauer, K. Ozato, and B.-Z. Levi
Interferon Regulatory Factor-8 Is Indispensable for the Expression of Promyelocytic Leukemia and the Formation of Nuclear Bodies in Myeloid Cells
J. Biol. Chem., February 23, 2007; 282(8): 5633 - 5640.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
K. Turcotte, S. Gauthier, A. Tuite, A. Mullick, D. Malo, and P. Gros
A mutation in the Icsbp1 gene causes susceptibility to infection and a chronic myeloid leukemia-like syndrome in BXH-2 mice
J. Exp. Med., March 21, 2005; 201(6): 881 - 890.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Baccarani, G. Martinelli, G. Rosti, E. Trabacchi, N. Testoni, S. Bassi, M. Amabile, S. Soverini, F. Castagnetti, D. Cilloni, et al.
Imatinib and pegylated human recombinant interferon-{alpha}2b in early chronic-phase chronic myeloid leukemia
Blood, December 15, 2004; 104(13): 4245 - 4251.
[Abstract] [Full Text] [PDF]

Home page
 ScienceHome page
N. P. Shah, C. Tran, F. Y. Lee, P. Chen, D. Norris, and C. L. Sawyers
Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor
Science, July 16, 2004; 305(5682): 399 - 401.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Burchert, D. Cai, L. C. Hofbauer, M. K. R. Samuelsson, E. P. Slater, J. Duyster, M. Ritter, A. Hochhaus, R. Muller, M. Eilers, et al.
Interferon consensus sequence binding protein (ICSBP; IRF-8) antagonizes BCR/ABL and down-regulates bcl-2
Blood, May 1, 2004; 103(9): 3480 - 3489.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. Tamura, H. J. Kong, C. Tunyaplin, H. Tsujimura, K. Calame, and K. Ozato
ICSBP/IRF-8 inhibits mitogenic activity of p210 Bcr/Abl in differentiating myeloid progenitor cells
Blood, December 15, 2003; 102(13): 4547 - 4554.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
H. Tsujimura, T. Nagamura-Inoue, T. Tamura, and K. Ozato
IFN Consensus Sequence Binding Protein/IFN Regulatory Factor-8 Guides Bone Marrow Progenitor Cells Toward the Macrophage Lineage
J. Immunol., August 1, 2002; 169(3): 1261 - 1269.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Kallies, F. Rosenbauer, M. Scheller, K.-P. Knobeloch, and I. Horak
Accumulation of c-Cbl and rapid termination of colony-stimulating factor 1 receptor signaling in interferon consensus sequence binding protein-deficient bone marrow-derived macrophages
Blood, May 1, 2002; 99(9): 3213 - 3219.
[Abstract] [Full Text] [PDF]


click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2001 by American Society of Hematology         Online ISSN: 1528-0020